| [1] |
Paplomata E, O'Regan R.The PI3K/AKT/mTOR pathway in breast cancer:targets,trials and biomarkers[J].Ther Adv Med Oncol,2014,6(4):154-166.
|
| [2] |
Jiang Y, Zhao X, Xiao Q, et al.Snail and Slug mediate tamoxifen resistance in breast cancer cells through activation of EGFR-ERK independent of epithelial-mesenchymal transition[J].J Mol Cell Biol,2014,6(4):352-354.
|
| [3] |
Heckler MM, Thakor H, Schafer CC, et al.ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer[J].FEBS J,2014,281(10):2431-2442.
|
| [4] |
Joo WD, Visintin I, Mor G.Targeted cancer therapy--are the days of systemic chemotherapy numbered? [J].Maturitas,2013,76(4):308-314.
|
| [5] |
Moerkens M, Zhang Y, Wester L, et al.Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation[J].BMC Cancer,2014,14:283.
|
| [6] |
Bergamaschi A,Katzenellenbogen BS.Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance [J].Oncogene, 2012,31(1):39-47.
|
| [7] |
Adams BD,Cowee DM,White BA.The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells [J].Mol Endocrinol,2009,23(8):1215-1230.
|
| [8] |
Zhao Y, Deng C, Lu W, et al.let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor α signaling in breast cancer[J].Mol Med, 2011, 17(11-12):1233-1241.
|
| [9] |
Ghayad SE, Vendrell JA, Ben Larbi S, et al.Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways[J].Int J Cancer,2010,126(2):545-562.
|
| [10] |
Oh AS, Lorant LA, Holloway JN, et al.Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells[J].Mol Endocrinol,2001,15(8):1344-1359.
|
| [11] |
Chen J, Hou R, Zhang X, et al.Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R,p38 MAPK and PI3K/Akt pathways[J].PLoS One, 2014,9(3):e91245.
|
| [12] |
Chen J, Sun L.Formononetin-induced apoptosis by activation of Ras/p38 mitogen-activated protein kinase in estrogen receptor-positive human breast cancer cells [J].Horm Metab Res,2012,44(13):943-948.
|
| [13] |
Hashimoto K, Tsuda H, Koizumi F, et al.Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer[J].Ann Oncol,2014,25(10):1973-1979.
|
| [14] |
Gholami S, Chen CH, Gao S, et al.Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer[J].Cancer Gene Ther,2014,21(7):283-289.
|
| [15] |
Eralp Y, Derin D, Ozluk Y, et al.MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer[J].Ann Oncol,2008,19(4):669-674.
|
| [16] |
Ward KR, Zhang KX, Somasiri AM, et al.Expression of activated M-Ras in a murine mammary epithelial cell line induces epithelial-mesenchymal transition and tumorigenesis[J].Oncogene,2004,23(6):1187-1196.
|
| [17] |
Hoeflich KP, O'Brien C, Boyd Z, et al.In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models [J].Clin Cancer Res, 2009,15(14):4649-4664.
|
| [18] |
Jing J, Greshock J, Holbrook JD, et al.Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212[J].Mol Cancer Ther,2012,11(3):720-729.
|
| [19] |
Mirzoeva OK, Das D, Heiser LM, et al.Basal subtype and MAPK/ERK kinase ( MEK )-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition[J].Cancer Res,2009,69(2):565-572.
|
| [20] |
Balko JM, Cook RS, Vaught DB, et al.Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance[J].Nat Med,2012,18(7):1052-1059.
|
| [21] |
Martin EC, Krebs AE, Burks HE, et al.miR-155 induced transcriptome changes in the MCF-7 breast cancer cell line leads to enhanced mitogen activated protein kinase signaling[J].Genes Cancer,2014,5(9-10):353-364.
|
| [22] |
Bayraktar S, Glück S.Molecularly targeted therapies for metastatic triple-negative breast cancer [J].Breast Cancer Res Treat,2013,138(1):21-35.
|
| [23] |
Kümler I, Tuxen MK, Nielsen DL.A systematic review of dual targeting in HER2-positive breast cancer [J].Cancer Treat Rev,2014,40(2):259-270.
|
| [24] |
Huang L, Chen T, Chen C, et al.Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracyclinebased neoadjuvant chemotherapy[J].World J Surg Oncol,2013,11:307.
|
| [25] |
Donnelly SM, Paplomata E, Peake BM, et al.P38 MAPK contributes to resistance and invasiveness of HER2-overexpressing breast cancer [J].Curr Med Chem, 2014,21(4):501-510.
|
| [26] |
Duman BB, Sahin B, Acikalin A, et al.PTEN, Akt, MAPK,p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer[J].J BUON, 2013, 18(1):44-50.
|
| [27] |
Aksamitiene E, Kholodenko BN, Kolch W, et al.PI3K/Aktsensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells[J].Cell Signal,2010,22(9):1369-1378.
|